X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock Has Average Price Target of $11.25 According to Brokerages

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) has been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $11.25.

A number of research analysts recently weighed in on XFOR shares. Wells Fargo & Company began coverage on shares of X4 Pharmaceuticals in a research note on Friday, July 10th. They set an “overweight” rating and a $11.00 target price on the stock. Weiss Ratings raised X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd.

X4 Pharmaceuticals Price Performance

NASDAQ XFOR opened at $2.91 on Thursday. The company has a current ratio of 11.30, a quick ratio of 11.02 and a debt-to-equity ratio of 0.49. X4 Pharmaceuticals has a 12 month low of $2.70 and a 12 month high of $4.83. The stock has a market cap of $288.53 million, a price-to-earnings ratio of -2.42 and a beta of 0.46. The company’s 50 day moving average is $3.70 and its two-hundred day moving average is $3.94.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. The business had revenue of $8.81 million during the quarter, compared to analyst estimates of $2.42 million. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 63.05%. As a group, research analysts anticipate that X4 Pharmaceuticals will post -0.67 earnings per share for the current year.

Key Stories Impacting X4 Pharmaceuticals

Here are the key news stories impacting X4 Pharmaceuticals this week:

• Positive Sentiment: The new facility replaces X4’s prior loan agreement, completes repayment of the existing facility, and provides additional funding for corporate and commercial activities. The financing could extend the company’s operating runway as it advances its rare-disease product and clinical programs. X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility
• Positive Sentiment: X4 expects to complete enrollment in its Phase 3 4WARD trial by the end of 2026, with topline results anticipated in the first half of 2028. The milestone gives investors a clearer timeline for a potentially important clinical catalyst. X4 Strengthens Cash Position Ahead of Key Phase 3 Milestones
• Positive Sentiment: Sell-side coverage remains generally constructive: six brokerages have an average “Moderate Buy” rating, including four buy ratings, one hold, and one sell rating. X4 Pharmaceuticals Stock Rated Moderate Buy
• Neutral Sentiment: X4 will host a virtual investor day on October 29 featuring key opinion leaders. The event may provide additional commercial and clinical detail, but its impact depends on the information disclosed. X4 Pharmaceuticals Investor Day
• Negative Sentiment: Although the financing improves liquidity, it is debt rather than equity, creating future repayment obligations and potential financing costs. The facility is also secured, increasing lender claims on company assets.
• Neutral Sentiment: A report citing October 9 short-interest data lists zero shares short and a zero-day days-to-cover ratio, which provides no evidence of meaningful short-covering demand; the “large increase” description appears inconsistent with the reported figure.

Insider Activity at X4 Pharmaceuticals

In related news, President John Volpone sold 24,576 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total value of $109,117.44. Following the transaction, the president directly owned 265,305 shares of the company’s stock, valued at approximately $1,177,954.20. The trade was a 8.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO David Kirske sold 11,767 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $2.86, for a total value of $33,653.62. Following the completion of the transaction, the chief financial officer directly owned 155,983 shares in the company, valued at approximately $446,111.38. This represents a 7.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 83,779 shares of company stock valued at $353,387. 1.13% of the stock is owned by company insiders.

Hedge Funds Weigh In On X4 Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Empery Asset Management LP bought a new position in shares of X4 Pharmaceuticals during the fourth quarter worth $35,804,000. Perceptive Advisors LLC increased its holdings in X4 Pharmaceuticals by 6.7% in the 1st quarter. Perceptive Advisors LLC now owns 6,737,648 shares of the company’s stock valued at $27,826,000 after acquiring an additional 423,196 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in X4 Pharmaceuticals in the 2nd quarter worth $917,000. Bank of America Corp DE lifted its stake in X4 Pharmaceuticals by 321.3% in the 1st quarter. Bank of America Corp DE now owns 150,676 shares of the company’s stock worth $622,000 after purchasing an additional 114,915 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of X4 Pharmaceuticals during the 2nd quarter valued at about $313,000. Hedge funds and other institutional investors own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases caused by immune and hematologic dysfunction. The company’s research centers on the CXCR4 biological pathway, which regulates the movement and retention of certain immune cells in the bone marrow and other tissues.

X4’s primary product is XOLREMDI (mavorixafor), an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration in 2024 for use in people aged 12 and older with WHIM syndrome.